Streetbeat News

Products Services

ANVS

Annovis Bio announced that its Phase 3 study of lead compound Buntanetap for Parkinson's disease has reached full enrollment in just nine months. The study is expected to conclude in November, with top-line assessment data available by the end of the year.

Portfolio Pulse from Benzinga Newsdesk

June 08, 2023 | 11:33 am

AAL

DAL

SAVE

UAL

Inbound flights to LaGuardia Airport have been grounded once again, potentially causing disruptions for airlines such as American Airlines (AAL), Delta Air Lines (DAL), Spirit Airlines (SAVE), and United Airlines (UAL).

Portfolio Pulse from Benzinga Newsdesk

June 08, 2023 | 11:30 am

UBER

Uber Technologies announced plans to launch peer-to-peer car sharing in North America, starting with Toronto and Boston. The move is part of the company's sustainability efforts and aims to curb emissions. The service, called Uber Carshare, allows customers to rent vehicles by the hour or day using the app.

Portfolio Pulse from Anusuya Lahiri

June 08, 2023 | 11:29 am

ONFO

Onfolio Holdings Inc. has posted two articles on its corporate website, providing insight into its growth strategy. The articles focus on Onfolio's corporate acquisition strategy and its plan to leverage AI across its subsidiaries.

Portfolio Pulse from Benzinga Newsdesk

June 08, 2023 | 11:26 am

GRTS

Gritstone bio has published interim results from its Phase 1 study of a self-amplifying mRNA vaccine against COVID-19 in Nature Communications. The results show promising safety and immunogenicity data.

Portfolio Pulse from Benzinga Newsdesk

June 08, 2023 | 11:09 am

AMZN

DIS

GOOG

GOOGL

META

NFLX

PARA

WBD

Amazon is considering launching an ad-supported Prime Video tier to expand its ad business and generate more entertainment revenue. The move could inspire other streaming platforms like Netflix and Disney to follow suit. Amazon is also in talks with Warner Bros. Discovery and Paramount Global to add ad-based tiers of their streaming services through Prime Video Channels.

Portfolio Pulse from Anusuya Lahiri

June 08, 2023 | 11:09 am

NSTG

Acrobat Genomics, Nanostring Technologies (NSTG), and the Illumina Accelerator have announced a collaboration with Stanford Medicine to discover new drug targets for gene editing-based therapeutics using GeoMx Digital Spatial Profiling Technology. The partnership aims to improve treatment options for patients suffering from interstitial lung diseases, such as idiopathic pulmonary fibrosis.

Portfolio Pulse from Benzinga Newsdesk

June 08, 2023 | 11:07 am

CING

Cingulate has completed its Phase 3 adult dose-optimization trial for CTX-1301, a treatment for Attention Deficit/Hyperactivity Disorder (ADHD). Results are expected in 3Q 2023, with pivotal Phase 3 trials in pediatric/adolescent patients scheduled for initiation in the same quarter.

Portfolio Pulse from Benzinga Newsdesk

June 08, 2023 | 11:04 am

LIAN

LianBio has completed enrollment in its pivotal Phase 3 LIBRA trial of TP-03 for Chinese patients with Demodex blepharitis. The trial aims to evaluate the safety and efficacy of TP-03 in treating the condition.

Portfolio Pulse from Benzinga Newsdesk

June 08, 2023 | 11:02 am

BCDA

BioCardia has been granted a patent in Japan for its Helix biotherapeutic delivery system, which is designed to improve the delivery of cell and gene therapies. The patent expands the company's intellectual property portfolio and may open up new market opportunities.

Portfolio Pulse from Benzinga Newsdesk

June 08, 2023 | 11:01 am